EU Pharma Law Overhaul Will Remake IP, Regulatory Strategy
The EU's proposed General Pharmaceutical Legislation will shorten and vary baseline drug-exclusivity periods, requiring life-sciences companies to integrate IP and regulatory planning much earlier in the product lifecycle.
The European Union is advancing its General Pharmaceutical Legislation (GPL), the most significant reform of its medicines framework in more than 20 years. The legislation will fundamentally alter the landscape for intellectual property and regulatory protections for innovative drugs, moving from a predictable timeline to a more variable, incentive-based system.
Sophisticated counsel and clients care because the GPL proposes to shorten baseline data and market exclusivity periods while making them conditional. Companies may earn extensions only by meeting new criteria such as addressing an unmet medical need or conducting specific comparator trials. This introduces significant uncertainty and requires a much tighter, earlier integration of regulatory, clinical, and IP strategy. Key changes also include a revised orphan-drug framework, an expanded 'Bolar' patent-infringement exemption for generics, and codified rules for 'skinny label' biosimilars.
The legislation is expected to enter into force by late 2026 and will generally apply to marketing applications filed after 2028. Companies should begin reassessing their development portfolios and lifecycle plans to align global filing strategies with the new EU reward structure and manage increasing divergence from the UK's regulatory regime.